|
|
This message has been approved by the NIH IRB. You are subscribed to receive research study announcements from the National Institutes of Health (NIH) Clinical Center. To learn more about this NIH study #002288-I or other studies, please call us at 833-JOIN-NIH.
Phase 1 Study of the Safety of an Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
The Epstein-Barr virus (EBV), which causes mono, affects over 90% of the global population and is linked to severe health conditions like cancer and autoimmune diseases. The National Institute of Allergy and Infectious Diseases seeks healthy volunteers aged 18–29 who live in the DMV area to help test a new experimental EBV vaccine.
The study involves undergoing a physical exam, providing blood and saliva samples, and receiving three doses of the vaccine. Volunteers will attend in-person visits at the NIH and may receive compensation of up to $2,170 over the course of the trial.
|
|
|
🌟 Interested in Participating in Research? 🌟
📢 The NIH Clinical Center is looking for volunteers to help advance medical discoveries!
📞 Call Us: 833-JOIN-NIH | TTY Users: Dial 7-1-1
📧 Email: ccopr@nih.gov
🔗 Learn More : go.nih.gov/6Ff5dzp
📌 Current Study: #002288-I
📍 Visit Us in Bethesda, MD | Metro Red Line (Medical Center)
📲 Stay Connected! NIH Clinical Center Instagram
|
|
|
|
